| pubmed-article:6760183 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6760183 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:6760183 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6760183 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:6760183 | lifeskim:mentions | umls-concept:C2717829 | lld:lifeskim |
| pubmed-article:6760183 | lifeskim:mentions | umls-concept:C1522609 | lld:lifeskim |
| pubmed-article:6760183 | lifeskim:mentions | umls-concept:C1554112 | lld:lifeskim |
| pubmed-article:6760183 | pubmed:dateCreated | 1983-3-17 | lld:pubmed |
| pubmed-article:6760183 | pubmed:abstractText | The authors present a group of 10 children with neuroblastoma treated with multidrug chemotherapy. 5 children were treated according to VCAD protocol and 5 children according to COMP protocol. The VCAD protocol seems to be useful in less advanced stages of neuroblastoma (stage I and II after incomplete excision) as a prophylactic chemotherapy and in stage III with parallel irradiation of tumoral mass. Chemotherapy with COMP protocol can provoke palliation and prolongation of survival time, and sometimes significant remission. Having support of the treatment with adequate irradiation it is possible to restrict tumoral mass and consolidate the result od chemotherapy. | lld:pubmed |
| pubmed-article:6760183 | pubmed:language | pol | lld:pubmed |
| pubmed-article:6760183 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6760183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6760183 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6760183 | pubmed:issn | 0303-2264 | lld:pubmed |
| pubmed-article:6760183 | pubmed:author | pubmed-author:PerekDD | lld:pubmed |
| pubmed-article:6760183 | pubmed:author | pubmed-author:Jurczyk-Procy... | lld:pubmed |
| pubmed-article:6760183 | pubmed:author | pubmed-author:Czerwi?skiWW | lld:pubmed |
| pubmed-article:6760183 | pubmed:author | pubmed-author:OrdyniecJJ | lld:pubmed |
| pubmed-article:6760183 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6760183 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:6760183 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6760183 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6760183 | pubmed:pagination | 177-87 | lld:pubmed |
| pubmed-article:6760183 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:meshHeading | pubmed-meshheading:6760183-... | lld:pubmed |
| pubmed-article:6760183 | pubmed:year | 1981 | lld:pubmed |
| pubmed-article:6760183 | pubmed:articleTitle | [Value of polychemotherapy in the treatment of children with neuroblastoma]. | lld:pubmed |
| pubmed-article:6760183 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6760183 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6760183 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6760183 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:6760183 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
